December 12, 2024 07:15 AM EST
R&D

Keros halts parts of Phase 2 PAH tri­al due to safe­ty, stock tanks 70%

Kyle LaHucik

Senior Reporter

Keros Ther­a­peu­tics said Thurs­day morn­ing it has vol­un­tar­i­ly halt­ed two of three dos­ing arms of its ex­per­i­men­tal drug in a Phase 2 tri­al due to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The brain is Eli Lil­ly's next tar­get for its obe­si­ty meds

Cor­cept’s ALS drug fails to im­prove func­tion in Phase 2 study

Lon­za looks to de­part cap­sule and health in­gre­di­ents as it un­der­goes re­struc­ture

The End­points 100: The biotech in­dus­try braces for Trump 2.0

Pleno rais­es $25M for mul­ti­omics test­ing, names new CEO

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times